Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

CardiAQ Valve Technologies Files Lawsuit Against Neovasc

June 6, 2014 By the Associated Press

CardiAQ Valve Technologies, a leader in the field of Transcatheter Mitral Valve Implantation, announced today that it has filed a federal lawsuit in Boston, Mass. against Neovasc, Inc. for fraud, misappropriation of trade secrets, breach of contract, and unfair and deceptive trade practices. In that lawsuit, CardiAQ seeks to enjoin Neovasc from further developing and commercializing Neovasc’s TMVI technology, including the Tiara, which is based upon CardiAQ trade secrets and know-how. CardiAQ also seeks to have one or more of its employees named as inventors on the Neovasc patent and patent applications that resulted from Neovasc improperly using CardiAQ’s proprietary technology.

In its complaint, CardiAQ alleges that in June of 2009, Neovasc approached CardiAQ and offered to provide services to support CardiAQ’s pre-existing development project for a minimally invasive implantable mitral valve, a product that is expected to help hundreds of thousands of patients suffering from mitral valve regurgitation, with a potential market estimated to be over two billion dollars. Neovasc presented itself as a contract manufacturer and trusted development partner that could provide tissue processing and valve assembly services for start-up heart valve companies. Based upon that representation, the two companies signed a confidentiality agreement and CardiAQ proceeded to openly share its intellectual property, proprietary designs, development updates, prototypes, and other confidential information. Those disclosures encompassed several years of ground-breaking valve prosthesis research and development by CardiAQ. The confidential relationship between Neovasc and CardiAQ continued for 10 months until April of 2010, when CardiAQ relocated to its current headquarters in Irvine, Calif. During that time, Neovasc never once communicated to CardiAQ that Neovasc was pursuing its own internal TMVI program. Neovasc has recently disclosed publicly that its internal TMVI development program began in 2009 – the same time Neovasc was working with CardiAQ under the confidentiality agreement. Moreover, the Neovasc engineer who served as the project leader for CardiAQ’s TMVI activities is also listed as the inventor on Neovasc’s patent and pending patent applications, which Neovasc filed within just a few weeks of its work with CardiAQ coming to an end.

“Coming from a background in contract manufacturing myself, it is shocking that a trusted development partner could take everything it had learned from us to create and advance its own internal TMVI program,” said Brent Ratz, co-founder, President and COO. “There is no doubt in my mind that we will prove that the intimate and early exposure to CardiAQ’s confidential and ground-breaking know-how taught Neovasc what do to and what not to do and greatly accelerated their internal development efforts.” “We recognize that Transcatheter Mitral Valve Implantation has become one of the most competitive spaces in medical devices and will remain that way for years to come,” said Rob Michiels, Chief Executive Officer. “As pioneers in this new field, CardiAQ set the standard for TMVI positioning and anchoring and we will defend our intellectual property and trade secrets vigorously. While it is not our preference to create any distraction from our technical and clinical efforts, this blatant disregard by Neovasc for confidentiality and honorable business practice, as set forth in the complaint, has left us with no choice.” Privately held CardiAQ, headquartered in Irvine, Calif., has developed a proprietary Transcatheter Mitral Valve (TMV) Implant that can be delivered through multiple delivery systems, including both Trans-femoral and Trans-apical. Through its unique anchoring mechanism that engages and utilizes the patient’s native mitral valve anatomy, physicians will be able to accurately and securely implant a new mitral valve within a beating heart, thus avoiding open-heart surgery. The CardiAQ procedures are designed to be performed in a cardiac catheterization laboratory or hybrid operating room. Ultimately, the procedure will result in less trauma to the patient and substantial potential cost-savings to the healthcare system.

Related Articles Read More >

Johnson & Johnson Office of Digital Innovation Leader Peter Schulam
Imagining the future of cloud-connected medical devices with Johnson & Johnson leaders
Withings Body Scan
Withings plans launch for Body Scan smart scale platform
BinaxNow COVID-19 Ag Card
Time recognizes Abbott offerings among this year’s 100 best inventions
Koya Medical’s Dayspring device
Koya Medical reports positive early results in Dayspring lymphedema trial

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech